Unlock instant, AI-driven research and patent intelligence for your innovation.

N-myristoyltransferase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for colorectal cancer

Inactive Publication Date: 2015-11-26
SHRIVASTAV ANURAAG
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a method for identifying patients at risk for colorectal cancer (CRC) by measuring the levels of a protein called N-myristoylatransferase 2 (NMT2) in a sample from the patient. The method may also involve measuring NMT2 levels in a sample from the patient using a specific antibody or measuring the levels of a gene that produces NMT2. If the NMT2 levels are above a certain threshold, the patient may be a candidate for further CRC screening, which may include a sigmoidoscopy or colonoscopy. The method may be useful for patients with a family history of CRC or those older than 55. The sample may include whole blood, peripheral blood mononuclear cells, T-cells, or CD4 cell samples. The patent also describes a specific reagent that is designed to measure NMT2. Overall, the invention provides a reliable and accurate method of identifying patients who may benefit from additional CRC screening.

Problems solved by technology

This adds complexity in measuring NMT1 in CRC patients as their CD4+ T cells are activated because of immune response due to several reasons including infection and or cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • N-myristoyltransferase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for colorectal cancer
  • N-myristoyltransferase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for colorectal cancer
  • N-myristoyltransferase 2 overexpression in peripheral blood and peripheral blood mononuclear cells is a marker for colorectal cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032]Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference.

[0033]Earlier reports revealed that NMT1 overexpression is most prominent in Peripheral Blood Mononuclear Cells (PBMC). In control subjects, NMT1 expression in PBMC and polymorphonuclear cells PMN ranged from negative to rare-weak positivity, with no more than 20% of cells ever staining positive. In contrast, CRC patients showed strong NMT1 staining in PBMC and PMNs. However in another report, it was suggested that expression of NMT1 is dependent on neutrophil activation state Shrivastav et al., 2010 Vet Res. 2010;41:9). A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Nucleic acid sequenceaaaaaaaaaa
Levelaaaaaaaaaa
Login to View More

Abstract

Described herein is the Identification of the NMT isozyme overexpressed in PB-MCs of colorectal cancer patients and the cell types overexpressing NMT2 in the PBMCs of CRC patients.

Description

PRIOR APPLICATION INFORMATION[0001]The instant application claims the benefit of U.S. Provisional Patent Application 61 / 730,694, filed Nov. 28, 2012.BACKGROUND OF THE INVENTION[0002]Cancer is the leading cause of death in Canada. Colorectal cancer (CRC), the second most fatal, has a 90% survival if treated at an early stage (CancerCare Manitoba, 2007; Population screening for colorectal cancer, 2006). Yet, every year over 600,000 people around the world die of CRC (Canadian Cancer Society, 2010). CRC arises from pre-malignant adenomatous polyps, which may take several years to develop into cancer. Genetics may also play a role, as 30% of CRC cases are familial (CancerCare Manitoba, 2007; Population screening for colorectal cancer, 2006). However, not all polyps develop into CRC and the vast majority of CRC cases are not familial. These statistics highlight the urgent need for reliable screening methods for early detection of CRC.Current CRC Screening Strategies Screening is the mean...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68G01N33/574
CPCC12Q1/6886G01N33/57419C12Q2600/112C12Q2600/158G01N2333/91057G01N2800/50
Inventor SHRIVASTAV, ANURAAG
Owner SHRIVASTAV ANURAAG